Lung Health and MSC Research: Early Investigations in COPD & Asthma

Chronic obstructive pulmonary disease (COPD) and asthma are two prevalent inflammatory airway diseases. COPD is characterized by progressive airflow limitation, emphysema, and chronic bronchitis, while asthma involves reversible airway obstruction, hyperresponsiveness, and eosinophilic or neutrophilic inflammation. Despite optimal pharmacotherapy (bronchodilators, inhaled corticosteroids, biologics for asthma) and pulmonary rehabilitation, many patients experience persistent symptoms and exacerbations. Preclinical research has explored mesenchymal stem cell (MSC)‑based interventions as a supportive adjunctive strategy, primarily through paracrine signaling and immunomodulation. This educational overview summarizes current evidence on MSC‑derived exosomes and cell‑based approaches in COPD and asthma, while emphasizing that no established clinical recommendations exist (Global Initiative for Asthma, 2025; Global Initiative for Chronic Obstructive Lung Disease, 2025).

Current Understanding of COPD and Asthma Pathophysiology

COPD involves chronic neutrophilic inflammation, oxidative stress, and protease‑antiprotease imbalance, leading to alveolar destruction and small airway fibrosis (Barnes, 2022). Asthma is driven by T‑helper type 2 (Th2) cytokines (IL‑4, IL‑5, IL‑13) in allergic asthma, or by neutrophilic and type 1 inflammation in non‑allergic phenotypes. Preclinical studies have shown that MSCs secrete anti‑inflammatory cytokines (IL‑10, TGF‑β) and growth factors (KGF, HGF) that reduce neutrophil infiltration, suppress Th2 responses, and promote repair of airway epithelium. Evidence from animal models (elastase‑induced emphysema; ovalbumin‑induced asthma) indicates that intravenous or intratracheal administration of MSCs is associated with reduced airspace enlargement, decreased airway hyperresponsiveness, and lower eosinophil counts (Weiss et al., 2019; Abreu et al., 2022). However, translation to human disease remains at an early stage.

What the Research Shows: Adjunctive Supportive Therapies

A phase I/II trial (NCT02216630) evaluated allogeneic MSCs in 62 patients with moderate‑to‑severe COPD. At 12 months, no significant difference in FEV1 or quality of life scores was observed compared to placebo, though a subgroup analysis suggested a reduction in C‑reactive protein levels (Leidy et al., 2021). In asthma, a small phase I study (NCT03792698) using intravenous MSCs in 10 patients with severe refractory asthma reported no serious adverse events and a trend toward reduced exacerbations, but the study was not powered for efficacy (Kang et al., 2023). Current systematic reviews conclude that MSC therapy for COPD and asthma is safe but lacks consistent evidence for meaningful clinical improvement (Chen et al., 2023; Cruz et al., 2024). MSC‑derived exosomes, which carry microRNAs (e.g., miR‑146a, miR‑21, miR‑133) and anti‑inflammatory proteins, are being investigated as a cell‑free alternative. One open‑label study reported that nebulized MSC‑exosomes were associated with reduced exacerbation frequency in COPD over six months, but the study lacked a control group (Khatri et al., 2022).

Integrating Rehabilitation and Nutrition with Regenerative Approaches

Pulmonary rehabilitation (exercise training, breathing techniques, and self‑management) remains a cornerstone of COPD and asthma management, with evidence showing improvements in exercise capacity, dyspnea, and reduced hospitalizations (McCarthy et al., 2022). For asthma, breathing exercises and physical activity have been shown to improve quality of life and reduce symptoms (Carson et al., 2020). Nutritional support — particularly high‑protein, antioxidant‑rich diets (e.g., Mediterranean pattern) and supplementation with omega‑3 fatty acids — has been associated with better respiratory muscle function, lower systemic inflammation, and improved asthma control in some studies (Schols & van de Bool, 2021; Wood et al., 2021). Emerging research suggests that combining structured rehabilitation with nutritional optimization may enhance the body’s endogenous repair mechanisms, creating a favorable environment for any adjunctive cellular therapy. For patients considering MSC‑based research protocols, a coordinated plan that includes pulmonary rehabilitation, smoking cessation (for COPD), allergen avoidance (for asthma), and optimal nutrition is essential.

Safety, Regulation, and the Importance of Conventional Care Continuation

Regulatory bodies classify MSC‑based interventions for COPD and asthma as adjunctive and not approved for clinical use outside of registered trials. Long‑term safety data from over 300 patients with respiratory diseases receiving MSCs report mild, transient adverse events (headache, low‑grade fever, transient dyspnea) without serious long‑term sequelae (Weiss et al., 2019). However, unregulated clinics offering unproven cell therapies pose significant risks, including infection, immunological reactions, and financial exploitation. Patients are strongly advised to continue conventional treatments and to consult their pulmonologist before considering any adjunctive therapy.